XBP1 and acute lymphoblastic leukemia: In order to discriminate off‐target effects of high concentrations of MKC‐8866 in blocking pre‐B ALL cells growth, we employed genetic loss of Xbp1 in parallel, and IRE1 targeting using MKC‐8866 revealed a similar phenotype compared with genetic loss of Xbp1.